Population PKPD modeling of BACE1 inhibitor-induced reduction in Aβ levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig

Pharmaceutical Research

Volumn 31, Issue 3, 2014, Pages 670-683

  Janson, Juliette ^a   Eketjäll, Susanna ^a   Tunblad, Karin ^a   Jeppsson, Fredrik ^a   Von Berg, Stefan ^a   Niva, Camilla ^a   Radesäter, Ann Cathrin ^a   Fälting, Johanna ^a   Visser, Sandra A G ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Alzheimer's disease; amyloid peptide; brain; cerebrospinal fluid; pharmacokinetic pharmacodynamic modeling

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; BRAIN PROTEIN; PLASMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN LEVEL; BRAIN TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENCY; FEMALE; GUINEA PIG; HALF LIFE TIME; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; POPULATION MODEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; CELL LINE; CELLS, CULTURED; ENZYME INHIBITORS; FEMALE; GUINEA PIGS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEURONS;

EID: 84895459713     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1189-y     Document Type: Article

References (60)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-44.
2. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362(4):329-44.
3. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2012;8(2):131-68.
4. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009;110(4):1129-34.
5. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698-712.
6. Wolfe MS. gamma-Secretase inhibitors and modulators for Alzheimer's disease. J Neurochem. 2012;120 Suppl 1:89-98.
7. Walsh DM, Teplow DB. Alzheimer's disease and the amyloid β-protein. Prog Mol Biol Transl Sci. 2012;107:101-24.
8. Lichtenthaler SF, Haass C, Steiner H. Regulated intramembrane proteolysis-lessons from amyloid precursor protein processing. J Neurochem. 2011;117(5):779-96.
9. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353- 6.
10. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ 42(43) and Aβ 40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ 42(43). Neuron. 1994;13(1):45-53.
11. Younkin SG. Evidence that Aβ 42 is the real culprit in Alzheimer's disease. Ann Neurol. 1995;37(3):287-8.
12. Steiner H, Capell A, Leimer U, Haass C. Genes and mechanisms involved in β-amyloid generation and Alzheimer's disease. Eur Arch Psychiatr Clin Neurosci. 1999;249(6):266-70.
13. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9(5):387-98.
14. Panza F, Frisardi V, Imbimbo BP, Capurso C, Logroscino G, Sancarlo D, et al. REVIEW: gamma-Secretase inhibitors for the treatment of Alzheimer's disease: the current state. CNS Neurosci Ther. 2010;16(5):272-84.
15. Kreft AF, Martone R, Porte A. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Aβ oligomer hypothesis of Alzheimer's disease. J Med Chem. 2009;52(20):6169-88.
16. Niva C, Parkinson J, Olsson F, van Schaick EA, Lundkvist J, Visser SAG. Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data. Eur J Clin Pharmacol. 2013. doi: 10.1007/s00228-012-1459-3.
17. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, et al. Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol Cell Neurosci. 1999;14(6):419-27.
18. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature. 1999;402(6761):537-40.
19. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286(5440):735-41.
20. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature. 1999;402(6761):533-7.
21. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein. Proc Natl Acad Sci U S A. 2000;97(4):1456-60.
22. Cole SL, Vassar R. BACE1 structure and function in health and Alzheimer's disease. Curr Alzheimer Res. 2008;5(2):100-20.
23. Stockley JH, O'Neill C. The proteins BACE1 and BACE2 and β-secretase activity in normal and Alzheimer's disease brain. Biochem Soc Trans. 2007;35(Pt 3):574-6.
24. Mullan M, Houlden H, Windelspecht M, Fidani L, Lombardi C, Diaz P, et al. Nat Genet. 1992;2(4):340-2.
25. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488(7409):96-9.
26. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem. 2007;282(36):26326-34.
27. Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, et al. BACE1 inhibition reduces endogenous Aβ and alters APP processing in wild-type mice. J Neurochem. 2006;99(6):1555-63.
28. Swahn BM, Kolmodin K, Karlstrom S, von Berg S, Soderman P, Holenz J, et al. Design and synthesis of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) inhibitors with in vivo brain reduction of β-Amyloid peptides. J Med Chem. 2012;55(21):9346-61.
29. Jeppsson F, Eketjall S, Janson J, Karlstrom S, Gustavsson S, Olsson LL, et al. Discovery of AZD3839, a potent and selective BACE1 clinical candidate for the treatment of Alzheimers Disease. J Biol Chem. 2012;287(49):41245-57.
30. Lu Y, Zhang L, Nolan CE, Becker SL, Atchison K, Robshaw AE, et al. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule gamma-secretase inhibitors. J Pharmacol Exp Ther. 2011;339(3):922-34.
31. Stachel SJ, Coburn CA, Sankaranarayanan S, Price EA, Wu G, Crouthamel M, et al. Macrocyclic inhibitors of β-secretase: functional activity in an animal model. J Med Chem. 2006;49(21):6147-50.
32. Stanton MG, Stauffer SR, Gregro AR, Steinbeiser M, Nantermet P, Sankaranarayanan S, et al. Discovery of isonicotinamide derived β-secretase inhibitors: in vivo reduction of β-amyloid. J Med Chem. 2007;50(15):3431-3.
33. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, et al. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Aβ pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010;30(33):11157-66.
34. Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, et al. β-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 2011;25(2):775-84.
35. Lu Y, Riddell D, Hajos-Korcsok E, Bales K, Wood KM, Nolan CE, et al. CSF Aβ As An Effect Biomarker For Brain Aβ Lowering Verified by Quantitative Preclinical Analyses. J Pharmacol Exp Ther. 2012;342(2):366-75.
36. Rueeger H, Lueoend R, Rogel O, Rondeau JM, Mobitz H, Machauer R, et al. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides. J Med Chem. 2012;55(7):3364-86.
37. Wood S, Wen PH, Zhang J, Zhu L, Luo Y, Babu-Khan S, et al. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors. J Pharmacol Exp Ther. 2012;343(2):460-7.
38. Weiss MM, Williamson T, Babu-Khan S, Bartberger MD, Brown J, Chen K, et al. Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid. J Med Chem. 2012;55(21):9009-24.
39. Dineen TA, Weiss MM, Williamson T, Acton P, Babu-Khan S, Bartberger MD, et al. Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem. 2012;55(21):9025-44.
40. Gravenfors Y, Viklund J, Blid J, Ginman T, Karlstrom S, Kihlstrom J, et al. New Aminoimidazoles as β-Secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in Brain. J Med Chem. 2012;55(21):9297-311.
41. Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, et al. First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther. 2009;328(1):131-40.
42. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci. 2011;31(46):16507-16.
43. Swahn BM, Holenz J, Kihlstrom J, Kolmodin K, Lindstrom J, Plobeck N, et al. Aminoimidazoles as BACE-1 inhibitors: the challenge to achieve in vivo brain efficacy. Bioorg Med Chem Lett. 2012;22(5):1854-9.
44. Bueters T, Dahlstrom J, Kvalvagnaes K, Betner I, Briem S. High-throughput analysis of standardized pharmacokinetic studies in the rat using sample pooling and UPLC-MS/MS. J Pharm Biomed Anal. 2011;55(5):1120-6.
45. Heisey SR. Brain and choroid plexus blood volumes in vertebrates. Comp Biochem Physiol. 1968;26(2):489-98.
46. Park S, Sinko PJ. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther. 2005;312(3):1249-56.
47. Borgegård T, Minidis A, Jureus A, Malmborg J, Rosqvist S, Gruber, S., Almqvist, H., et al. In vivo analysis using a presenilin-1-specific inhibitor: Presenilin 1- containing g-secretase complexes mediate the majority of CNS Ab production in the mouse. 3 2011;1:30-45.
48. Friden M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos. 2009;37(6):1226-33.
49. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21(4):457-78.
50. Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabo B, et al. The novel β-secretase inhibitor KMI-429 reduces amyloid β peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem. 2006;96(2):533-40.
51. Liu L, Duff K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp 2008 Nov 10;(21).
52. Truong AP, Toth G, Probst GD, Sealy JM, Bowers S, Wone DW, et al. Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett. 2010;20(21):6231-6.
53. Lu Y. Integrating experimentation and quantitative modeling to enhance discovery of Beta amyloid lowering therapeutics for Alzheimer's disease. Front Pharmacol. 2012;3(177):1-6.
54. Danhof M, Van der Graaf PH, Jonker DM, Visser SAG, Zuideveld KP. Mechanism-based pharmacokinetic-pharmacodynamic modeling for the prediction of in vivo drug concentration-effect relationships -application in drug candidate selection and lead optimization. 2007. Comprehensive Medicinal Chemistry (2nd Ed.) Volume 5: "ADME-Tox: The Fate of Drugs in the Body". Editors Bernard Testa and Han van de Waterbeemd.
55. Bueters T, Ploeger BA, Visser SA. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives. Drug Discov Today. 2013. doi: 10.1016/j.drudis.2013.05.001.
56. Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim Biophys Acta. 2008;1780(5):819-25.
57. Beck M, Bruckner MK, Holzer M, Kaap S, Pannicke T, Arendt T, et al. Guinea-pig primary cell cultures provide a model to study expression and amyloidogenic processing of endogenous amyloid precursor protein. Neuroscience. 2000;95(1):243-54.
58. Yang HC, Chai X, Mosior M, Kohn W, Boggs LN, Erickson JA, et al. Biochemical and kinetic characterization of BACE1: investigation into the putative species-specificity for β- and β'-cleavage sites by human and murine BACE1. J Neurochem. 2004;91(6):1249-59.
59. Vandermeeren M, Geraerts M, Pype S, Dillen L, Van Hove C, Mercken M. The functional gamma-secretase inhibitor prevents production of amyloid β 1-34 in human and murine cell lines. Neurosci Lett. 2001;315(3):145-8.
60. Gabrielsson J, Fjellstrom O, Ulander J, Rowley M, Van Der Graaf PH. Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. Curr Top Med Chem. 2011;11(4):404-18.